<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02519049</url>
  </required_header>
  <id_info>
    <org_study_id>1287</org_study_id>
    <nct_id>NCT02519049</nct_id>
  </id_info>
  <brief_title>11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)</brief_title>
  <official_title>Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective exploratory study specifically investigating the role of 11C-Methionine PET/CT&#xD;
      imaging in patients affected by Malignant Pleural Mesothelioma (MPM) and candidate to&#xD;
      pleurodesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study, lasting 36 months including an estimated period of&#xD;
      24 months for the enrollment and max 12 months of follow-up. All patients affected by MPM and&#xD;
      referred to our Institution eligible for therapeutic pleurodesis and subsequent platinum- and&#xD;
      pemetrexed-based chemotherapy will be enrolled. In all cases patients will be investigated&#xD;
      with 11C-Methionine PET/CT and 18F-FDG PET/CT before talc pleurodesis, one week after and at&#xD;
      the end of three cycles of chemotherapy.&#xD;
&#xD;
      A minimum number of 20 patients will be considered for the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis</measure>
    <time_frame>Change from Baseline in SUVmax up to 1 week after talc pleurodesis.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Mesothelioma, Malignant</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy specimen&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients affected by MPM and referred to our Institution for therapeutic pleurodesis&#xD;
        and subsequent platinum- and pemetrexed-based chemotherapy will be enrolled. A minimum&#xD;
        number of 20 patients will be considered for the analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with an histological diagnosis of MPM eligible for pleurodesis and scheduled&#xD;
             to undergo platinum- and pemetrexed-based chemotherapy.&#xD;
&#xD;
          -  obtained informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients age &lt;18 years&#xD;
&#xD;
          -  pregnancy or breast-feeding;&#xD;
&#xD;
          -  patients affected by other malignancies within the last 3 years;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Egesta Lopci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Clinical and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75. doi: 10.1007/s00259-014-2960-y. Epub 2014 Nov 18.</citation>
    <PMID>25403555</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A. Assessment of tumor response in malignant pleural mesothelioma. Cancer Treat Rev. 2007 Oct;33(6):533-41. Epub 2007 Aug 30. Review.</citation>
    <PMID>17764849</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Chiti A, Santoro A. 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N Engl J Med. 2007 Nov 8;357(19):1982-4.</citation>
    <PMID>17989397</PMID>
  </reference>
  <reference>
    <citation>Lopci E, Novellis P, Testori A, Rahal D, Voulaz E, Bottoni E, Ferraroli GM, Crepaldi A, Ceresoli GL, Perrino M, Castello A, Alloisio M, Veronesi G, Zucali PA. In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nucl Med Commun. 2019 Nov;40(11):1179-1186. doi: 10.1097/MNM.0000000000001078.</citation>
    <PMID>31568271</PMID>
  </reference>
  <reference>
    <citation>Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A. Prognostic and predictive role of [(18) F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med. 2017 Oct;6(10):2287-2296. doi: 10.1002/cam4.1182. Epub 2017 Sep 21.</citation>
    <PMID>28941158</PMID>
  </reference>
  <reference>
    <citation>Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL. Clinical staging of malignant pleural mesothelioma: current perspectives. Lung Cancer (Auckl). 2017 Aug 18;8:127-139. doi: 10.2147/LCTT.S102113. eCollection 2017. Review.</citation>
    <PMID>28860886</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesothelioma</keyword>
  <keyword>11C-methionine PET</keyword>
  <keyword>talc pleurodesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

